Tobias Arkenau (@EllipsesCMO) profile picture

Tobias Arkenau

@EllipsesCMO
 England, United Kingdom
Joined May 2012
  • Tweets180
  • Following133
  • Followers133
14Media
Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)Photo by Tobias Arkenau (@EllipsesCMO)
Explore the cutting-edge of lung cancer treatment with @EllipsesCMO. Learn about the latest breakthroughs in clinical trials and the growing demand for next-generation therapies. Read more: pharmafocus.com/collections/… #LungCancer #PrecisionMedicine #Innovation #EllipsesPharma

Next generation treatments and clinical trials for non-small cell lung cancer

Professor tobias arkenau from ellipses pharma explores the need and potential for next generation treatments as well as the global need to keep improving t

pharmafocus.com
1
85
AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: ellipses.life/ellipses-pharm… #PrecisionMedicine #EllipsesPharma
2
2
84
EP0031, our next-gen RET inhibitor, receives FDA Orphan Drug Designation. A crucial step in advancing cancer treatments. #OrphanDrug #EP0031 #EllipsesPharma ellipses.life/ellipses-ep003…
Image from @EllipsesPharma (@ellipsespharma)
3
3
85
📄 Access the poster presentation for Asset EP0031, shared by @EllipsesCMO at @AACR Boston. Dive into the details and join us in advancing cancer research!💡ellipses.life/wp-content/upl… #AACR2023 #CancerInnovation 🚀
2
85
#Targets23 Great work from Drs. @AriMarinel @mihaela_aldea and others on characterizing outcomes in #RET NSCLC post progression on selective inhibitors: patterns of progression, response to subsequent lines of therapy. – at Huntington Avenue - Prudential Center, Boston
Image from Stephen V Liu, MD (@StephenVLiu)
2
5
1
39
5,209
I was happy to see Dr. @ElenaGarralda again - presenting work on EP0031, a next generation #RET inhibitor with impressive efficacy after selective RET inhibitors and CNS efficacy. #Targets23
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
Image from Stephen V Liu, MD (@StephenVLiu)
1
8
30
2,826
Thrilled to be a speaker at the Economist Impact World Cancer Series Europe 2023 on Sept 20th - 21st. Join me and the panel as we discuss Women's Cancer. Together, we can make a meaningful impact! #EconWorldCancerSeries #CancerResearch #WomensHealth
50
Tobias Arkenau retweeted
RET Renegades (@RetRenegades) profile picture
RET Renegades@RetRenegades22 Jun 2022
Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With ... - goo.gl/alerts/1QWMK #GoogleAlerts #RETcancer #Lungcancer #researchmaters
Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-alt...

Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With Advanced RET-alt...

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovat...

businesswire.com
1
🎯 🧬 KL590586 (A400/EP0031) A next-generation selective RET inhibitor in patients with RET-altered solid tumors. ORR 60% and DCR 95% for all tumor types and doses. 🫁 In NSCLC: ORR 81% in 1L and 70% in 2L. Also 🧠 activity proven #ASCO23 #LCSM
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
Image from Dr. Antonio Calles 🫁🚭 (@Tony_Calles)
1
14
25
3,310
Next generation selective RET inhibitor EP0031/A400 - convincing and solid data presented by Prof Zhou.
Image from Tobias Arkenau (@EllipsesCMO)
4
114
Tobias Arkenau retweeted
ESMO - Eur. Oncology (@myESMO) profile picture
ESMO - Eur. Oncology
@myESMO1 Mar 2023
The burden of bureaucracy in clinical research has increased for investigators & clinical research teams. ESMO proposes a framework to streamline clinical research & reduce the bureaucracy in clinical trials, promoting better care for cancer patients. 🔗annalsofoncology.org/article…
Image from ESMO - Eur. Oncology (@myESMO)
Jose Luis Perez-Gracia (@JlgraciaMD) profile pictureJose Luis Perez-Gracia@JlgraciaMD11 Feb 2023
1/ Bureaucracy is overwhelming Clinical Research! ESMO proposes principles to improve Sponsoring and Monitoring of Clinical Trials and promote patient welfare Follow thread for examples & proposals, share if you agree! #StreamlineClinicalResearch @myESMO bit.ly/3XZ63WY
Image from Jose Luis Perez-Gracia (@JlgraciaMD)
4
32
9
62
35,479
Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors precisiononcologynews.com/ca…
1
We are excited to share our latest cancer research insights through more than 140 abstracts and presentations at #ASCO22. Read about where you can find our scientific experts at this year’s annual meeting. sarahcannon.com/about/newsro…
Home

Home

HCA Healthcare announces collaboration with Johnson & Johnson to address key healthcare clinical and industry issues Read article 2 min read HCA Healthcare to donate up to $400,000 to Kentucky flood...

hcahealthcaretoday.com
3
9
Excited to be on our first call for the new ⁦@ASCO⁩ monthly plenary series. See attached for dates of presentations and submissions. Exciting to get data out there within 5-6 weeks of submission. Monthly Plenary Series | ASCO asco.org/meetings-education/…
6
22
Tobias Arkenau retweeted
VJHemOnc (@VJHemOnc) profile picture
VJHemOnc
@VJHemOnc11 Nov 2020
Be the first to hear the latest HemOnc news and best practice from the world’s leading experts 👨‍🔬👩‍🔬 Stay tuned for videos, podcasts and articles published live from the latest virtual meetings! #HemOnc #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #BleedingDisorders
Image from VJHemOnc (@VJHemOnc)
8
31
1
219
Happy Fourth of July! Wishing you a safe and enjoyable holiday with friends and family. #July4th
Photo of a woman and a girl that reads "4th of July".

ALT Photo of a woman and a girl that reads "4th of July".

1
1
1
Tobias Arkenau retweeted
VJ Oncology (@VJOncology) profile picture
VJ Oncology
@VJOncology19 Jun 2021
🕙 Just 10 days to go until ESMO #WorldGI2021 starts and @VJOncology are excited to report on the biggest news from the meeting Check out 👉 vjoncology.com 👈 for exclusive interviews, podcasts and more! @myESMO #CRCSM #HPBCsm #STCsm #ESOCsm #GICancer #ayacsm
2
2
Tobias Arkenau retweeted
VJ Oncology (@VJOncology) profile picture
VJ Oncology
@VJOncology7 Jun 2021
Enjoying the gastrointestinal cancer oral abstract session? 🤔 Register to our upcoming #VJSession, a roundtable discussion on the latest learnings in GI from #ASCO21 Register here ➡️tinyurl.com/the-gi-session @ASCO @OncoAlert #GIsm
Image from VJ Oncology (@VJOncology)
1
3
Tobias Arkenau retweeted
VJ Oncology (@VJOncology) profile picture
VJ Oncology
@VJOncology6 Jun 2021
Register now for @VJOncology's post-ASCO VJSessions! Join us for a series of roundtable discussions with #oncology experts to review key highlights from #ASCO21 Click for more details 👇👇 GI: tinyurl.com/GI-session GU: tinyurl.com/gu-sessions Breast: tinyurl.com/breast-sessions
Image from VJ Oncology (@VJOncology)
3
1
4
Tobias Arkenau retweeted
EORTC (@EORTC) profile picture
EORTC@EORTC5 May 2021
#MCCRWorkshop The Workshop is organised by @EORTC @myESMO and @AACR and has provided training to over 1800 investigators from all over the world since its’ inception in 1999. Apply NOW eortc.org/mccr #clinicaltrialdesign #clinicaltrials
Image from EORTC (@EORTC)
15
2
21
Load more